We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.50 | 1.59% | 32.00 | 146,816 | 08:39:19 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 31.00 | 33.00 | 32.00 | 31.50 | 31.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | -3.19M | -0.0449 | -7.13 | 22.39M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:30:02 | O | 1,000 | 31.20 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/7/2024 | 11:10 | ALNC |  Sareum Co-Founder & CEO Tim Mitchell steps back after twenty years |
| 10/7/2024 | 07:00 | UK RNS | Sareum Holdings PLC Management Changes |
| 01/7/2024 | 11:09 | ALNC | TRADING UPDATES: Rainbow Rare and Ecora strike Phalaborwa deal |
| 01/7/2024 | 07:00 | UK RNS | Sareum Holdings PLC Positive Data from SDC-1801 Phase 1 Clinical Trial |
| 30/5/2024 | 07:00 | UK RNS | Sareum Holdings PLC Appointment of Sole Broker |
| 07/5/2024 | 14:10 | UK RNS | Sareum Holdings PLC Exercise of Warrants |
| 23/4/2024 | 07:00 | UK RNS | Sareum Holdings PLC Final Issue of RiverFort Subscription Shares |
| 19/4/2024 | 12:16 | ALNC | IN BRIEF: Sareum falls as issues shares to RiverFort Global |
| 19/4/2024 | 11:35 | UK RNS | Sareum Holdings PLC Issue of RiverFort Subscription Shares |
| 15/4/2024 | 15:28 | UK RNS | Sareum Holdings PLC Issue of RiverFort Subscription Shares |
Sareum (SAR) Share Charts1 Year Sareum Chart |
|
1 Month Sareum Chart |
Intraday Sareum Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 26/7/2024 | 22:47 | Sareum 2015 | 17,816 |
| 28/11/2022 | 20:37 | SRA737 | 16 |
| 05/8/2021 | 08:49 | No more rns until current project closed | - |
| 04/7/2021 | 20:52 | SAR 2013 , SHORT THE ARSE OUT OF IT THREAD | 326 |
| 08/1/2021 | 18:09 | SAR - Sareum Holdings drug discovery | 370 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 15:30:03 | 31.20 | 1,000 | 312.00 | O |
| 2024-07-26 15:29:39 | 33.00 | 100 | 33.00 | O |
| 2024-07-26 15:28:51 | 33.00 | 100 | 33.00 | O |
| 2024-07-26 15:26:29 | 32.80 | 3,036 | 995.81 | O |
| 2024-07-26 14:31:00 | 31.50 | 4,754 | 1,497.51 | O |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Sareum Daily Update Sareum Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SAR. The last closing price for Sareum was 31.50p.Sareum currently has 71,069,416 shares in issue. The market capitalisation of Sareum is £22,742,213. Sareum has a price to earnings ratio (PE ratio) of -7.13. This morning SAR shares opened at 31.50p |
Posted at 08/7/2024 14:00 by peaceandlove It's called sarcasm Boo 👻 Hoo. 🤦🏻 BTW, why do you always use foul language?What you and I say and indeed anyone else for that matter doesn't affect the share price The share price will continue to fall until Sareum announce how they're going to fund the continuation of their clinical trial. Don't you have any opinions or facts about this company? Very odd! I've given my thoughts on sareum. The whole idea of this board is to share information and give opinions, which means both sides to the argument. |
Posted at 05/7/2024 11:36 by wolfofwallstreets Sobering post on lse..t is clear that there are reasons other than the much over used, go to excuse of mm manipulation, for the share price stagnating after an RNS stating progress and positivity. I’ve read for years posts about the big pharmas have us on their radar, patents running out ,yet their is no evidence or proof of any of that. Just guesswork or hope. Finance has got to be a concern and the fact the only deal we could get previously was the RF model . Going forward my concern is that more dilution is the way they’ll go ,as to date ,there’s no evidence of a partnership to take this forward . Time will tell but I would have hoped we could have moved forward in terms of share price after the recent RNS. It’s always jam tomorrow with Sar. |
Posted at 02/7/2024 09:17 by peaceandlove At last a honest post on LSE. Well done 👏 👏👏&#Reality10 Posts: 59 Price: 39.00 No Opinion RE: Share price.Today 09:12 If you listen to SOG, Laz, carter, bailiff annd countless others etc. they are super rampers you will get trapped in this share. What has happened here is, Sareums data package is late again. Yes it’s very very positive so far, but we have to wait another 3 months until potentially end of Q3 for the full data read out, so it’s late as the market expected end of Q2. SOG nothing personal, your knowledge is far above anyone’s here when it comes to the science, im the first to admit it, I even enjoy reading your postings, but your constantly criticising people with a more realistic view of what is going on here with regards to share price expectations. Laz, carter and Baliff are nothing more than cheer leaders that offer nothing but hopium. So until this data comes out and unless some news on say 737 comes out which is a possibility, this share price will slide as we will witness in the coming days and weeks. Even with the data readout, funding has to be sorted out so again don’t get caught out by all the ramping. Long term money will be made here but all you rampers stop the ramping you look foolish. Did I sell a large chunk of my money yesterday, yes I did, but I have a large holding still |
Posted at 01/7/2024 07:32 by yzf750 Sareum Holdings plc("Sareum" or the "Company")Positive Data from SDC-1801 Phase 1 Clinical TrialCambridge, UK, 1 July 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce positive topline data from its Phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases.Following the dosing of the final cohort in the Multiple Ascending Dose stage of the trial, and review of the initial data by the Safety Review Committee, the Company reports that:· Blood plasma levels of SDC-1801 significantly in excess of the predicted therapeutic exposure were achieved, with a half-life of between 17 and 20 hours observed, which suggests that once-daily dosing will be possible*· No deaths or serious adverse events due to SDC-1801 were reported· Although data remains blinded, there appear to be no significant changes in blood cell counts or increases in serum creatinine levels, which may be dose limiting side-effects of brepocitinib, currently the most advanced TYK2/JAK1 dual inhibitor *Half-life is an estimation of the time it takes for an initial concentration of SDC-1801 to be reduced by half in the body.The Company expects that further data, unblinded from drug/placebo recipients, including details of any mild or moderate adverse events and biomarkers of TYK2 and/or JAK1 inhibition, will be available in Q3 2024.Dr Tim Mitchell, Chief Executive Officer of Sareum, commented: "We are delighted that the dosing of subjects in the SDC-1801 clinical trial has been completed successfully and without any serious adverse events. We look forward to building a strong data package to advance SDC-1801 to the next stage of its development." Dr John Reader, Chief Scientific Officer of Sareum, added: "The success of this stage of the clinical trial demonstrates that high blood levels of a dual TYK2/JAK1 kinase inhibitor can be achieved without serious side effects. Together with the long half-life observed, we believe this potentially gives SDC-1801 significant advantages over its competitors. We're grateful to the volunteers who participated in this trial, and to the clinical staff who enabled its timely completion."- END - |
Posted at 22/6/2024 22:48 by criticalthinker1 Just go back to the early days and scrutinise their affiliations.Here is a bit re my prior post...not making it easy for those who are not invested proteins that accelerate structure determination using x-ray crystallography. Once the structure is determined, the Company's innovative fragment screening platform is used to identify novel chemical templates designed to interact with the target protein. Sareum then uses its high-throughput medicinal chemistry platform to rapidly optimise these molecules and develop the most promising into potential drug candidates. Sareum aims to successfully deliver drug candidates for licensing to larger pharmaceutical companies at the pre-clinical or early clinical trials stage. This is funded by provision of its specialist drug discovery capabilities to partners in the pharmaceutical and biotechnology industries. Sareum joined the AIM market of the London Stock Exchange in October 2004 and trades under the symbol SAR. For further information, please visit www.sareum.co.uk This information is provided by RNS The company news service from the London Stock Exchange Just dyor ...just saying politely...those goes way back and was always Tim and Charles vision...albeit they happened upon something very unique ...yet others jumped on the bandwagon...yet they realised small molecular deliverance was paramount. It's very interesting when you read into their specific. Hence why I'm here and Thoth was also. Time will tell. What I liked about lse in the early days was freedom of discussion....i just feel that the posters on lse step on egg shells...being just about correct without the ability to say...what about that post re the USA military...the submarine patent...the positive review re a coronavirus...the patents that had to go to China ...mhra throwing us under the 🚌 Ph. Rf...you name it....GSK are sweating their bollards here...snd AZ KNOW IT All best Steadydanny |
Posted at 10/6/2024 17:40 by barkbooo Peaceandlove - “When I post on Sareum I post facts and informed opinions” really? lolPeaceandlove - peaceandlove23 Mar '24 - 17:17 - 15513 of 17515 “I truly believe this'll go below 1p” peaceandlove25 Mar '24 - 11:56 - 15523 of 17515 “free fallin', now I'm free fallin', now I'm)Free fallin' (free fallin', now I'm free fallin', now I'm) peaceandlove26 Mar '24 - 13:39 - 15548 of 17515 “This is going below 1p a share - mark this post.” peaceandlove27 Mar '24 - 15:06 - 15565 of 17515 “100% I will continue to tell the truth” peaceandlove28 Mar '24 - 07:34 - 15580 of 17515 “My advice to existing shareholders is get your money out while you still can.” peaceandlove30 Mar '24 - 07:53 - 15640 of 17515 “Sareum is 10p a share” peaceandlove1 Apr '24 - 09:42 - 15656 of 17515 “😆 |
Posted at 04/6/2024 20:29 by criticalthinker1 I think Emma is in the queue Wolfie. It's tiring looking in on here and seeing the seriously unbalanced and deranged responses you give.The clue was for all to see last year in a RNS posted by Sareum (below) and since that RNS things have seen a great leap in the progression of 1801 and 1802 will follow and 737 ticking along despite your lies to acknowledge the proof I had it was still progressing. RNS Sareum announces two new granted patents, including first patent specifically for SDC-1801 Cambridge, UK, 26 June 2023 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that the first patent specifically relating to SDC-1801, its lead TYK2/JAK1 kinase inhibitor, has been granted in China. Further, a patent has been formally granted for SDC-1802 and several analogues in the United States, extending the scope of protection beyond immuno-oncology. Dr John Reader, Sareum's Chief Scientific Officer, commented: "We're delighted to have the first patent granted for SDC-1801, our lead development programme which recently advanced into a Phase 1a clinical trial in Australia. We look forward to being able to strengthen our intellectual property around this asset in other territories in due course." "Separately, we are really pleased to have extended the scope of patent protection for SDC-1802 in the US. Although oncology remains the primary focus of this asset, this bulwarks our intellectual property position and gives us optionality to explore opportunities in other therapeutic areas." SDC-1801 is a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune dermatological condition affecting more than 60 million adults worldwide, with a market size for potential treatments estimated to be worth more than US$30 billion. Sareum recently announced that it has begun dosing healthy subjects in a Phase 1a clinical trial for SDC-1801, in Australia. The China National Intellectual Property Administration (CNIPA) has officially issued patent number CN113056456B, safeguarding SDC-1801 and medical applications of it in treating inflammatory or immune disorders. This is the first patent grant issued to Sareum for SDC-1801 in any territory. Patent applications in Europe (EP3864009), the US (US2021387981) and other territories are still under review. SDC-1802 is a TYK2/JAK1 inhibitor being developed for cancer immunotherapy. Sareum continues to work on the translational studies needed to support the development of SDC-1802, defining the optimal cancer application prior to completing toxicology and manufacturing studies. The United States Patent and Trademark Office (USPTO) has formally granted patent number US 11,673,870 B2 specifically covering the treatment of autoimmune disorders with SDC-1802 and several analogues. While Sareum has previously secured international patents providing comprehensive protection for the compound SDC-1802, this patent extends its scope in the US beyond immuno-oncology. Just read that and see where we are now! Look at the various avenues the drugs can be adopted in! Good luck to genuine holders. I'm convinced as I mentioned before PH are trying to play the share price before imminent fantastic update. They are a despicable company. Its very interesting the timing of the trolls appearing. |
Posted at 04/6/2024 15:39 by peaceandlove A recap me thinks.1)MHRA refused Sareum a clinical trial. One can only imagine why. I suspect they felt the novel formulation is not a sufficient innovation to expose fit and healthy volunteer-patients to the risks of the trial. 2) The Clinical Trial is a phase 1 protocol. This assesses only the basic safety of the new molecule and has nothing to do with whether it will work or not. It can be compared with base camp for the climb to the summit of Everest. 3)The company admits that to go forward through and beyond the Phase 1 trial, it will have to go back to investors to raise more money. This is not good and could result in a dilution of your share holding or a share price reduction. I leave it to your imagination as to the struggle Sareum will have if the Phase 1 outcome is unfavourable. 4) No revenue 5) No license deals 6) share price down 68% since this time last year despite Sareum having their first clinical trial after 20 years. All facts! Not so cool Boo 👻 Hoo needs to stay of the special brew. PMSL |
Posted at 25/5/2024 20:17 by criticalthinker1 Re 1801 this from 2023..oh how we have come on 4.5. SAR-20347 SAR-20347 is an oral inhibitor of Tyk2 and Jak1 with selectivity over Jak2 and Jak3. Preclinical assays demonstrated that SAR-20347 inhibited IL-12, IL-23 and IFN-α signaling [22]. Both Tyk2 mutant mice and mice treated with SAR-20347 showed significant reduction of IL-6 and IL-17 in imiquimod-induced skin lesions, but only SAR-20347-treated mice presented reduced levels of IL-23, decreased keratinocyte proliferation and improved clinical score [22]. In addition, SAR-20347-treated mice manifested lower IL-17 gene expression compared to Tyk2 mutant mice [22]. In this model, Works et al. demonstrated that SAR-20347 treated mice showed an almost complete loss of IL-22 gene expression in skin lesions, and they postulate that SAR-20347 would impair the ability of Th17 and γδ cells to induce IL-22 [22]. IL-22 is required for development of autoreactive Th17 cells [77,78]. However, not only IL-22 production was impaired, since IL-22 signaling was also affected in vitro in a human colonic cell line, and STAT3 phosphorylation dependent of IL-22 was completely blocked [22]. Blocking both Tyk2 and Jak1 in this study was more effective than inhibition of Tyk2 alone at reducing psoriasis-like disease severity, keratinocyte proliferation, as well as IL-23, IL-17, IL-6, IL-22, and antimicrobial peptide gene expression, and the authors postulate that targeting a combination of Jak1 and Tyk2 using an orally available inhibitor may be a viable approach for treating psoriasis, but currently there are no ongoing or completed clinical trials for SAR-20347 [22]. The bodies in 'control' of certain narratives know full well what Sareum is undertaking. This is going to make Novacyt huge rise look like a blip. 1802 is going to be on the tail end and the results of 1801 will be very significant in its future All best Steadydanny |
Posted at 02/5/2024 13:11 by peaceandlove "Why are you bothered when you don’t own sar shares"Because if Sareum do go straight into Phase 2a and then 2b (assuming the safety of the molecule is satisfactory) and are approved by the Australian Regulator Authority to administer to sick patients, then for me that'd be the time to invest in Sareum. I'd be convienced they would indeed have a strong case in achieving a licensing deal or takeover. At present there is no revenue, more dilution on the cards, The Phase 1 clinical Trial only assesses the basic safety of the molecule and has nothing to do with weather it will work or not. share price down over 60% YTD and over 80% since inception (nearly 20 years ago). No license deals in the pipeline. Board look they're in a comfort zone.... I could go on.... You, Barkbooo, etc just put my comments down, as would the LSE posters even though I believe I've given a fair counter argument as to why I feel Sar are a long way of anything positive. Someone has to challenge the happy clappers - their constant ramping about £billion dollar deals etc needs to be called out. The happy clapping fairies dancing around with nothing but positives is not only wrong, but dangerous to new investors. Listening to them since January this year and your £10k investment would be worth £4k. Hope you understand......? There're always two sides to every story! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
